Story
Replimune Shares Surge After FDA Grants Accelerated Approval for Melanoma Drug Tudriqev

Shares of Replimune Group Inc. (REPL) surged in pre-market trading after the U.S. Food and Drug Administration (FDA) granted accelerated approval for its melanoma therapy, Tudriqev. The decision, announced late Thursday, clears the drug for use in combination with Bristol Myers Squibb’s nivolumab for adults with advanced, unresectable cutaneous melanoma that has progressed despite prior anti-PD-1 treatment.
FDA Reverses Stance on Trial Data
The approval marks a significant turnaround for Replimune, as the FDA had previously rejected the therapy on two separate occasions, citing insufficient evidence of effectiveness from the single-arm IGNYTE study. The agency has now granted accelerated approval based on data from that same Phase 1/2 trial.
Key findings from the IGNYTE study that supported the approval include:
- An objective response rate (ORR) of 24.2% among 91 efficacy-evaluable patients.
- A median duration of response (mDOR) of 14.1 months.
Because the approval was granted under the accelerated pathway, which relies on surrogate endpoints, Replimune will be required to verify the drug's clinical benefit in a confirmatory trial. The company's ongoing Phase 3 IGNYTE-3 study is expected to serve this purpose.
AdMarket Reaction and Analyst Outlook
Following the news, Replimune's stock reached a new 52-week high of $13.90 in pre-market activity. The FDA's decision was preceded by a series of positive analyst revisions. Leerink upgraded Replimune to Outperform and raised its price target to $17.00 from $11.00, with an analyst expressing "high conviction" in the approval and anticipating "strong demand."
Wedbush also upgraded the stock to Outperform from Neutral, setting a new price target of $12.00. Analysts see Tudriqev as a more accessible alternative to existing treatments like Iovance Biotherapeutics’ cell therapy Amtagvi, which involves a more complex treatment process and has a more challenging side-effect profile.
A Critical Lifeline for Replimune
The approval provides a crucial path forward for a therapy that the company had reportedly considered discontinuing if it faced another regulatory setback. The combination of the FDA green light and a supportive analyst community has provided a significant boost to the company's prospects in the competitive oncology market.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.